This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levy, N. L. Articles by Day, E. D. Search for Related Content PubMed PubMed Citation Articles by Levy, N. L. Articles by Day, E. D.

In Vitro Demonstration of Cell-mediated Immunity to Human Brain Tumors¹

Divisions of Immunology and Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710

Our studies showed that patients with primary intracranial neoplasms, both well differentiated and anaplastic, intra- and extracerebral, possessed peripheral blood lymphocytes that in vitro were specifically cytotoxic to tissue-cultured, autogenous tumor cells. Some studies suggested antigenic cross-reactivity between glioblastoma cells from different patients and, moreover, between glioblastoma and melanoma cells. One melanoma patient possessed lymphocytes cytotoxic to his tumor cells and to allogeneic glioblastoma cells, as well as to the tumor cells and normal glial cells, but not to the normal fibroblasts, of a patient with a ganglioglioma.

¹ Supported by AEC Contract AT-(40-1)-3195, Institutional Grants from the American Cancer Society, USPHS Research Grant CA11898-01 from the National Cancer Institute, the Center for the Study of Aging (USPHS Grant HD-00668), and a grant from the Research Triangle Foundation. Presented in part at the Proceedings of the Federation of American Societies for Experimental Biology, April 1971.

² Recipient of NIH Special Fellowship 1 F11 NS02320-01 from the National Institute of Neurological Diseases and Stroke.

Received 8/24/71. Accepted 11/19/71.

This article has been cited by other articles:

				J. Tang, P. Flomenberg, L. Harshyne, L. Kenyon, and D. W. Andrews Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells Clin. Cancer Res., July 15, 2005; 11(14): 5292 - 5299. [Abstract] [Full Text] [PDF]